2026-10-12T18:37:00Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33994983 2026-09-25T12:19:40Z category_7 portal_147 item_type_3 month_year_09_2026

Supplemental Material for: Measuring Parkinson’s disease progression with wearable sensors: results from a phase 2 clinical trial of cinpanemab figshare admin karger (2628495) Christoph M. Kanzler (25109859) Tzu-Ying Liu (4515604) Miroslaw Brys (25109860) Jesse M. Cedarbaum (814368) Sheraz Khan (3549479) Krishna Praneeth Kilambi (136926) Tara Aldoory (25109863) Peter R. Bergethon (25109864) Minhua Yang (6182222) Jeremy R. Edgerton (25109865) Medicine Medicine <p dir="ltr"><b>Introduction:</b> Digital health technologies (DHTs) are promising to provide novel endpoints in Parkinson’s Disease (PD) but often lack evidence for large-scale clinical trial use. This report evaluates the sensitivity to longitudinal change of QMA-PD, a pre-specified digital composite score derived from wearable sensors, in 357 people with PD participating in the SPARK phase 2 trial of cinpanemab.</p><p dir="ltr"><b>Methods:</b> The QMA-PD composite score is derived from 36 digital measures collected during 5 in-clinic motor tasks. Measurement properties of the QMA-PD were analyzed, including sensitivity to longitudinal changes based on mixed models for repeated measures.</p><p dir="ltr"><b>Results:</b> The QMA-PD showed longitudinal changes in PD-related motor signs, indicating disease progression, but did not show superior sensitivity to longitudinal changes compared to the rater-based MDS-UPDRS Part 3. In line with clinical and biomarker results, the QMA-PD did not show differences between the cinpanemab and placebo groups at 52 weeks.</p><p dir="ltr"><b>Conclusions:</b> These findings suggest that the substantial inter‑patient variability in disease progression may dominate effects of increased measurement precision, limiting the ability to assess the utility of digital measures in population-level analyses. Alternatively, different DHT measurement strategies may be needed to generate endpoints with greater sensitivity to longitudinal change than currently available clinical outcome assessments.</p> 2026-09-25T12:19:40Z Dataset Dataset 10.6084/m9.figshare.33994983.v1 https://figshare.com/articles/dataset/Supplemental_Material_for_Measuring_Parkinson_s_disease_progression_with_wearable_sensors_results_from_a_phase_2_clinical_trial_of_cinpanemab/33994983 CC BY 4.0